Hi @Fastback6666,
yes, it’s compelling adult EAP data for you & me.
But no, IMO the FDA will want another trial - at least on the go - for approval purposes. Could we get AA? Maybe, but a case needs to be at least acknowledged by the FDA before pursuing it. I don’t recall seeing any FDA support for an adult AA.
Best case as I see it will differ on MSBs desired strategic position in the aGVHD market - if it’s 1st line or 2nd line, then the trial will be required & assessment vs Rux will be necessary. If 3rd line, then EAP may be good enough.
But it won’t be good enough IMO for BMT CTN. They want to see the cells go head to head vs the small molecules. So do I.
Cheer up. Off-label post-paediatric approval will boost MSB sales revenue in the meantime. All those physicians know the cells work too. And there’s always the prospect of early completion.
Cheers
- Forums
- ASX - By Stock
- MSB
- ASX Hot too!
ASX Hot too!, page-301
-
- There are more pages in this discussion • 371 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.0¢ | 86854 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 0.965 |
1 | 23000 | 0.960 |
4 | 56273 | 0.955 |
5 | 46225 | 0.950 |
2 | 65500 | 0.945 |
Price($) | Vol. | No. |
---|---|---|
0.970 | 50000 | 2 |
0.975 | 20000 | 1 |
0.980 | 894 | 1 |
0.985 | 48122 | 2 |
0.990 | 54328 | 5 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
MSB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online